Major Scope
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Leukemia
- Bladder Cancer
- Kidney Cancer
- Endometrial Cancer
- Oncology Case Reports
- Radiation Therapy
Abstract
Citation: Clin Oncol. 2024;9(1):2093.DOI: 10.25107/2474-1663-v9-id2093
99mTc-PSMA in a Patient with Metastatic Castration- Resistant Prostate Cancer with False-Positive Post-Therapy 99mTc-MDP Bone Scan
Alarcon S and Paredes E
Department of Nuclear Medicine, Clinica Ricardo Palma, Lima, Peru
*Correspondance to: Shirley Marcela Alarcón Santisteban
PDF Full Text Case Report | Open Access
Abstract:
Prostate cancer is the most frequent cancer diagnosis in men and the third cause of cancer-related death in men in Peru. The detection of lesions with overexpression of PSMA receptors in metastatic prostate cancer cells is detectable with PET/CT-PSMA, however due to its high cost and low availability in our country, we used the SPECT-CT study with 99mTc-PSMA, which allows the localization of lesions with PSMA surface antigen expression, limiting the false positives that usually give conventional studies with SPECT-CT with 99mTc-MDP. Bone scan usually present the flare phenomenon in those patients who have been irradiated and generate false positives in the control study, however with the use of 99mTc-PSMA we reduce false positives by evidencing the avidity of PSMA active tumor cells that overexpress it, avoiding unnecessary treatment.
Keywords:
Cite the Article:
Alarcon S, Paredes E. 99mTc-PSMA in a Patient with Metastatic Castration- Resistant Prostate Cancer with False- Positive Post-Therapy 99mTc-MDP Bone Scan. Clin Oncol. 2024;9:2093..
Journal Basic Info
- Impact Factor: 3.231**
- H-Index: 11
- ISSN: 2474-1663
- DOI: 10.25107/2474-1663
- PubMed NLM ID: 101705590